Search published articles


Showing 8 results for Fatemi

Dr. F. Jalali Farahani, Dr. S. Zolgaghari, Dr. A. Talebian, Dr. A. Azarkeivan, Dr. M. Maghsudlu, Dr. M. Sarmadi, Dr. Sh. Fatemi, A. Shahrabi, Z. Taherkhani,
Volume 6, Issue 1 (Spring 2009)
Abstract

  Abstract

 Background and Objectives

 Thalassemia is the most common hereditary anemia in Iran. Despite improved hematologic care, multi endocrine dysfunction is a common complication in these patients. The main objective of this study was to estimate the prevalence of thyroid dysfunction in patients including both thalassemia major and thalassemia intermedia.

 

 Materials and Methods

 In this descriptive cross sectional study, a questionnaire was designed for 195 patients who were reffered to Iranian Blood Transfusion Organization Clinical Laboratory of Tehran from Thalassemia Clinic in Winter 2007. The following items were brought up in the questionnaire: sex, age, height, weight, splenectomy time, amount of transfused blood, blood transfusion interval, desferoxamine dosage, type of thalassemia (major or intermedia), serum thyroid hormones, and ferritin levels. Then, the correlation of thyroid functional status with age, serum ferritin level, type of thalassemia, splenectomy and desferoxamine dosage was evaluated in both β thalassemia major and thalassemia intermedia groups.

 

 Results

 We had 178(91.3%) β thalassemia major (50.6% male, 49.4% female with the mean age of 17.2 ± 8 years) and 17(8.7%) thalassemia intermedia (23.5% male, 76.5% female with the mean age of 23.2 ± 8.8 years). One hundred sixty two (83.1%) patients were euthyroid, 27 (13.8%) had subclinical hypothyroidism (CI 95%= 9-18.6), and 6(3.1%) were primary hypothyroid (CI 95%= 0.7-5.5). Mean ferritin levels for euthyroid group were 1923 ± 1470 ng/ml, for subclinical hypothyroidism group 1723 ± 1346 ng/ml, and for primary hypothyroidism 1569 ± 734 ng/ml, respectively. No significant correlation was found between abnormal thyroid function (subclinical and primary hypothyroidism) and serum ferritin levels (p=0.55), age (p=0.11) , type of thalassemia (p=0.68), splenectomy (p=0.62) and desferoxamine dosage (p=0.33).

 

 Conclusions

 Based on our results, thalassemia patients present a sort of thyroid dysfunction such as hypothyroidism. So, more effective treatment with desferoxamine and regular follow up of patients for evaluation of thyroid function satus are recommended.

 

  Key words : Thalassemia, Thyroid Gland, Hypothyroidism


Dr. R. Ghilian, Dr. S.h. Hekmati Moghaddam, Dr. A. Fatemi, H. Eslamieh, Dr. M. Dargahi,
Volume 7, Issue 4 (Winter 2011)
Abstract

Abstract Background and Objectives The aim of this study was to determine the frequency of brucellosis and the titer of anti-brucella antibody by the Wright and ELISA methods in blood donors in Yazd province sensitivity and specificity rates of these two methods were also compared. Materials and Methods This descriptive/analytical cross-sectional study was performed on 300 healthy donors admitted to Yazd Blood Transfusion Center. All of them were interviewed, examined, and tested by routine serologic diagnostic tests of brucellosis, including rapid Wright, standard tube Wright test, 2-ME (2-mercapto ethanol), and ELISA (enzyme-linked immunosorbent assay). Results Nineteen (6.3%) out of 300 participants had a tube Wright titer of 1:80 (5.7% of men and 14.3% of women). By ELISA method, 17 persons (5.7%) had positive IgG anti-Brucella antibody. The 2-ME test was positive in only 2 cases (0.6%). The sensitivity, specificity, positive predictive, and negative predictive values of ELISA compared to Wright test were 5.3%, 94.7%, 6.3%, and 93.7%, respectively. Conclusions If a titer of 1:80 is defined to be the criterion of contamination with brucella, it should not be considered negligible in blood donors of Yazd. Key words: Brucella, Blood Donors, ELISA, Iran
M. Azzizadeh Forouzi, T. Ramazani, M.h. Safarizadeh, R. Alimirzaei, S. Rahbarifar, M.s. Fatemi,
Volume 11, Issue 4 (winter 2015)
Abstract

  Abstract

 Background and Objectives

 Patients with thalassemia experience complex symptoms and encounter many physical and mental problems. This problems can affect their quality of life. This study is carried out to find the relationship between psychological characteristics and the quality of life of patients with thalassemia.

  

 Materials and Methods

 A cross-sectional descriptive study was conducted to determine the psychological reactions and quality of life of patients with thalassemia in Kerman. The instruments for data gathering were DASS (42) and Quality of life (SF 36). Data analyses were done by central indexes, chi2, ANOVA, and t-test.

  

 Results

 The results showed that 49.3% were male and 50.7 % female. The age range varied from 15 to 22.6 years. The results of 8 domains of the quality of life indicates that the score of physical domain was higher than the mental domain (p < 0.0001). The results regarding the psychological reactions showed that the patients had levels of “depression, anxiety, and stress” with 44.9%, 53.6%, and 50.7%, respectively. The results also showed there were significant differences between the quality of life and psychological reactions of patients.

  

 Conclusions

 The results showed the patients were at risk of psychological problems and the poor quality of life in mental domains thus, all domains of quality of life and mental problems of patients must be considered by caregivers, and holistic care of patients also should be one of the priorities of caring and curing.

  

  


Z. Ameri, S. Ghiasi, Dr. A.r. Farsinejad, M. Ehsan, S. Aghajani, N. Pur Yazdan Panah, Sh. Kazemzadeh, Dr. A. Fatemi,
Volume 14, Issue 3 (Atumn 2017)
Abstract

Abstract
Background and Objectives
Telomerase-targeted therapy for cancer has received great attention because telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. This study aimed to investigate the effects of telomerase inhibitor MST-312, a chemically modified derivative of epigallocatechin gallate (EGCG), on apoptosis of myeloma cell line U266.
 
Materials and Methods
In an Experimental study, U266 cells were treated with different concentrations of MST-312 at different times; then, cell viability by trypan blue exclusion assay, cell metabolic activity by MTT assay, and cell apoptosis by Annexin V Apoptosis Detection Kit were measured. To further investigate apoptosis, BAX and BCL2 gene expression of the treated cells was investigated by the quantitative Real-Time PCR.
 
Results
MST-312 exerted a dose-dependent short-term cytotoxic effect on myeloma cells. Over 50% decrease in the viability of treated cells was seen in 8 μM concentration of MST-312 within 48 h. The cytotoxic effect of MST-312 was concentration-dependent, with approximately 25, 46, and 62% reduction in metabolic activity after 48 h exposure to 2, 4, and 8 μM of MST-312, respectively. Gene expression analysis showed downregulation of antiapoptotic gene Bcl-2 and upregulation of apoptopic gene BAX.
 
Conclusions 
Inhibition of telomerase activity by MST-312 represents a novel treatment strategy for Multiple Myeloma cancer.
 

 


A.r. Moradabadi, Dr. A.r. Farsinejad, Dr. A. Fatemi,
Volume 14, Issue 4 (Winter 2017)
Abstract

Abstract
Background and Objectives
Chronic myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders. They are heterogeneous in symptoms and mainly consist of Philadelphia chromosome positive (Ph+) and negative (Ph-). The Ph- group includes polycythemia Vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and other rare disorders. In the latter group, substitution of phenylalanine for valine at codon 617 (JAK2V617F), could be relevant to the disease. In this study we used modified PCR-RFLP to detect JAK2 V617 F mutation in chronic myeloproliferative neoplasms.
 
Materials and Methods
In this cross sectional study, for detection of JAK2 V617 F mutation, 47 subjects were enrolled and peripheral blood samples were collected between 2015 and 2016. The samples were collected from the clinic center of Arak city and diagnosed to be JAK2 V617F positive by TaqMan probe and sequencing methods. All samples were investigated for the mutation by modified PCR-RFLP using specific primers and BsaXI restriction enzyme. The data were analyzed by t-test.
 
Results
Our modified PCR-RFLP for detection of JAK2 V617F mutation showed the same results as TaqMan probe and sequencing standard methods. In this study we have positive and negative samples and a standard method whose sensitivity and specificity was calculated to be 100% .
 
Conclusions 
Our modified PCR-RFLP is a comparable method with gold standard methods, TaqMan probe and sequencing, for detection of JAK2 V617F mutation. The advantages of this modified method include its ability to detect JAK2 V617F in homozygote and heterozygote conditions, and the presence of the internal digestion control.
 
 


T. Akbari Saeed, Dr. M. Ahmadi Zeydabadi, Dr. A. Fatemi, Dr. A.r. Farsinejad,
Volume 15, Issue 1 (Spring 2018)
Abstract

Abstract
Background and Objectives
Tissue engineering as a potential method was developed for the repair of tissue damages. The basic prerequisite for tissue engineering is in vitro growth and proliferation of cells on the scaffolds. One of the important new biomaterials that was introduced in 2006 by Choukroun and colleagues is fibrin membrane and now is only used as an autologous biomaterial. However, the use of fibrin as allogeneic membrane due to the risk of transmission of viral and bacterial diseases is very limited. Perhaps the decontamination of fibrin membranes be a key solution to overcome the limitations of its application in tissue engineering.
 
Materials and Methods
In this experimental study, fibrin membranes prepared of FFP by three methods were decontaminated. Cell viability and toxicity of 3T3 fibroblast cell on membranes of fibrin that was decontaminated were evaluated by MTT assay. Statistical analysis of data was performed by using Paired-Sample t-test.
 
Results
In case of both decontaminated and contaminated fibrin membranes, the survival of fibroblast cells 24 and 48 hours after exposure to the membrane increased significantly (P>0.01); however, 72 hours after exposure, the proliferation reduced and there were evidence of cells apoptosis.
 
Conclusions 
Based on these findings it can be concluded that Fibrin membranes by providing an appropriate background and releasing growth factors enhance the proliferative potential and increased survival of the cells. This feature is not affected by the decontamination methods of fibrin membranes.
 

 
 


N. Ghasemimehr, Z. Yazdani, Dr. A.r. Farsinejad, R. Mirzaee Khalilabadi, Dr. A. Fatemi,
Volume 15, Issue 2 (Summer 2018)
Abstract

Abstract
Background and Objectives
There have been continuous efforts in telomerase-targeted therapy for cancer treatment because telomerase expression is significantly increased in about 85- 90% of human cancers while its expression is usually silenced in normal cells.
 
Materials and Methods
Throughout this experimental study, NALM-6 cells were treated with different concentrations of telomerase inhibitor, MST-312 at different times. Then, cell viability and metabolic activity were evaluated by trypan blue and MTT assays; cell apoptosis was also evaluated by flow cytometry using Annexin V Apoptosis Detection Kit. In addition, the expression of BAX and BCL2 genes was evaluated in the treated cells using Quantitative Real-time PCR.
 
Results
A dose-and time-dependent decrease was observed in the viability of NALM-6 cells after exposure with different concentration of MST-312. Over 50% decrease was observed in the viability of the cells treated with 8 μM of MST-312 after 48 h. The cytotoxic effect of MST-312 was dose- dependent, with approximately 6, 19.69 and 56.9% reduction in metabolic activity of NALM-6 cells after 48 h exposure with 2, 4, and 8 μM of MST-312, respectively. Approximately 20% apoptosis was observed in NALM-6 cells treated with 4μM of MST-312 after 48 h.  Gene expression analysis also showed that 4μM of MST-312 led to upregulation of BAX and downregulation of Bcl-2 genes.
 
Conclusions 
Inhibition of telomerase activity by MST-312 can be proposed as a new candidate for the treatment of acute lymphoblastic leukemia.
 

 

Z. Yazdani, Z. Mousavi, N. Ghasemi Mehr, Dr. A. Fatemi, Dr. A.r. Farsinezhad, Dr. Gh.h. Hassan Shahi,
Volume 16, Issue 1 (Spring 2019)
Abstract

Abstract
Background and Objectives
Acute myeloid leukemia (AML) is a heterogeneous cancer that is caused by various pathologic mechanisms. Cancer cells change the chemokine system. CCR5 receptor has an indirect effect on cancer progression by controlling immune response against the tumor. This receptor can accelerate tumor growth and play a significant role in tumor metastasis, and it has been shown that CCR5 antagonists inhibit tumor growth. In this study, we decided to investigate the CCR5 receptor in AML patients after the first stage chemotherapy.
 
Materials and Methods
This case-control study was conducted in Kerman University of Medical Sciences during 2017-2018. Twenty five AML patients with monocytic differentiation post the first stage of chemotherapy (the fourth week after chemotherapy), after being examined for the peripheral blood smear and confirmed for the absence of blast cells, were evaluated by flow cytometry for the expression of the CCR5 receptor on the peripheral blood leukocytes population and were compared with healthy controls. The data were analyzed by independent T-Test and SPSS (version 22).
 
Results
The results of this study showed that the mean expression of CCR-5 in the patients group post-chemotherapy (1.04 ± 0.26) was similar with the healthy control group (1.04 ± 0.16).  Moreover, there was no meaningful difference between the two groups.
 
Conclusions  
Chemotherapy has caused the CCR5 receptor expression to be in its base state compared to the healthy control group. Other chemokine syndromes and their receptors could be examined to find out which role would play a significant role in the recurrence of patients.
 




Page 1 from 1     

© 2025 CC BY-NC 4.0 | Scientific Journal of Iran Blood Transfus Organ

Designed & Developed by : Yektaweb